Inhaled corticosteroid doses for the BTS, NICE and SIGN asthma guideline

Right Decisions
Asthma pathway (BTS, NICE, SIGN) [SIGN 244]
Back
Additional information and resources
Inhaled corticosteroid doses for the BTS, NICE and SIGN asthma guideline

Update your RDS mobile app to v4.7.2 to download toolkits even when website is down.

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. You will see that each toolkit has a small QR code icon in the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively update to the latest release - RDS app version 4.7.1 - to see this improvement.

Updating to this latest version of the RDS app is also strongly recommended to get the full benefits of the new resilience arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

We have developed the tables in this guide to support the recommendations on inhaled corticosteroid (ICS) dosages in the BTS, NICE and SIGN guideline on asthma. They indicate low, moderate and high ICS dosages for adult and paediatric maintenance therapy.

The dosages given are based on the following sources:

manufacturers’ summaries of product characteristics (SPCs)
the Global Initiative for Asthma (2024)
the British National Formulary (BNF)
the British National Formulary for children (BNFC).

The tables do not make any recommendations about a particular product’s place in therapy, nor should these be inferred.

Resources

Use the button below to access this item.

Access this resource